Antibody Shows Promise Against Obesity-related Liver Disease and Atherosclerosis in Mice
Federation of American Societies for Experimental Biology (FASEB)Latest research in the FASEB Journal reveals an antibody called bFKB1 improves liver disease and atherosclerosis in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH), which is associated with obesity.